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Abstract 
Purpose: To improve the effectiveness and reduce the systemic side effects of methylprednisolone in 
traumatic spinal injuries, its polymeric implants were prepared using chitosan and sodium alginate as 
the biocompatible polymers. 
Methods: Implants of methylprednisolone sodium succinate (MPSS) were prepared by molding the 
drug-loaded polymeric mass obtained after ionotropic gelation method. The prepared implants were 
evaluated for drug loading, in vitro drug release and in vivo performance in traumatic spinal-injury rat 
model with paraplegia. 
Results: All the implant formulations were light pale solid matrix with smooth texture. Implants showed 
86.56 ± 2.07 % drug loading. Drug release was 89.29 ± 1.25 % at the end of 7 days. Motor function was 
evaluated in traumatic spinal injury-induced rats in terms of its movement on the horizontal bar. At the 
end of 7 days, the test group showed the activity score (4.75 ± 0.02) slightly higher than that of standard 
(4.62 ± 0.25), but the difference was not statistically different (p > 0.05).  
Conclusion: MPSS-loaded implants produces good recovery in traumatic spinal-injury rats.     
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Implants are invasive polymeric delivery devices 
which are intended to release the drug in the 
injected/inserted body cavity in a very slow 
manner for prolonged periods of time which may 
extend from a week to few months and even to 
many years. These may be prepared either from 
non-biodegradable polymers or from 
biodegradable polymers. Non-biodegradable 
implants are needed to be removed by another 
surgical procedure after the expected completion 
of drug in the polymeric implant. Though invasive 
nature of procedures is a limitation of use of 
implant, easy termination of therapy (if required 
in case of adverse effects) by removal of implant 
is a unique advantage of implants. Unlike 
conventional parenteral dosage forms drug 
delivery by implants can reduce dosage 
frequency, provide prolonged duration of action 
and improve the patient compliance [1,2]. 
Implants can deliver drug in the 
microenvironment of target site or in vicinity of 
target site with maximizing the drug utilization 
and providing local as well as systemic effects. 
Implants may be solid matrix type or reservoir 
type devices with or without special drug 
releasing mechanisms like molds, tablets, 
pellets, osmotic pumps, infusion pumps etc. or 
may be in situ gelling systems which upon 
injection get converted in to a gel with contact of 
body fluids, change in temperature or pH [3,4]. 
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Spinal column is the most sophisticated and 
complex biological target site for drug delivery. 
Traumatic spinal cord injury is one of the most 
complex injuries to manage. Spinal injury leads 
to permanent disability, paraplegia, tetraplegia 
and over all decreased life expectancy [5-7]. 
There is no cure of spinal cord injury but efforts 
can be made to cope with the effects of primary 
and secondary spinal injury.  
 
The management of neuropathic pain and 
inflammation is the prime objective in treatment 
of spinal injuries. Many potent nonsteroidal anti-
inflammatory drugs (NSAIDs) and steroids (in 
high dosage) are administered for the same. But 
to provide the prolonged and target specific drug 
delivery various NSAIDs and steroids have been 
investigated for intrathecal administration so as 
to provide improved therapeutic effect [8,9]. 
Various biodegradable polymers have been 
investigated for preparing scaffolds or polymeric 
network/platform/implant of developing for 
neuroprotective and neuroregenerative drug 
delivery systems in spinal cord injuries [10,11]. 
 
Methylprednisolone sodium succinate (MPSS) is 
the glucocorticoid used in effective management 
of traumatic spinal injury [12]. It has been 
reported to show significant recovery from tissue 
damage, neuropathic pain and inflammation. 
Studies have also shown improvement in motor 
nerve activity with the use of MPSS in spinal 
injury [13,14]. This study aims to develop the 
polymeric implantable device of MPSS and to 
study its effect on traumatic spinal injured rats 






Methylprednisolone sodium succinate (MPSS), 
chitosan 75 % deacylated and sodium alginate 
(SA) were obtained from Sigma Aldrich Japan. 
Rests of the chemicals were of analytical grade.  
 
Preparation of polymeric hydrogels of MPSS 
 
Implants of MPSS were prepared by molding of 
drug loaded polymeric mass obtained after the 
ionotropic gelation method (Table 1). Accurately 
weighed quantity of sodium alginate was 
dispersed in distilled water and stirred at 200 rpm 
for 30 min meanwhile weighed quantity of the 
drug was dispersed onto the dispersion of 
alginate. This drug-alginate solution was mixed 
with 4 % solution of chitosan in acetone with 
stirring with addition of propylene glycol. Then 
this solution was kept in teflon molds with flat 
bottom and slowly 2 % aqueous calcium chloride 
solution was sprayed for 10 minutes till the mass 
attained the gel like consistency. The molds 
containing polymeric matrix loaded with the drug 
was frozen at -10 ± 1 oC for rigidization 
overnight.  The prepared implant molds were 
taken out to room temperature and then cut into 
small cubic pieces of desired size with a surgical 
blade. For hardening these implants were kept in 
a desiccator rich in vapors of formaldehyde 
which were produced by keeping 37 % v/v 
formaldehyde solution at the bottom of the 
desiccator for 48 h. After hardening, the implants 
were taken out, air dried for 4 days for removing 
traces of formaldehyde from the implants. Finally 
the prepared implants were sterilized by ethylene 
oxide and then packed in butter paper for storage 
in cool dark place in an aseptic environment. 
 




(% w/w) 1  
Sodium alginate  
(% w/w) 2 
Chitosan* 
(% w/w) 1 
Polypropylene glycol 
(% v/v) 5 




One implant (15 × 15 × 15 mm) was dissolved in 
50 ml of methanol with continuous stirring (200 
rpm) at 37 ± 1 oC) for 1 h (n=6). One mL sample 
was withdrawn, diluted suitably and then 
analysed spectrophotometrically. 
 
In vitro release of drug 
 
In vitro drug release study was performed 
according to a reported method [15]. One implant 
(15 × 15 × 15 mm) was kept in a tightly closed 
vial with pH 7.4 buffer (10 ml) as media. Several 
such vials were kept on an incubator shaker (at 
37 ± 1.0 oC). For taking sample a single vial was 
withdrawn at definite time interval till 7 days and 
analysed spectrophotometrically for drug release 
(n = 3). 
 
In vivo study on traumatic spinal-injury rats 
 
Healthy male Wistar rats (200 - 240 g) were used 
for the study. After procurement, experiment was 
carried after giving 3 - 4 days of resting and 
acclimatization.  The rats were fed standard diet 
and water ad libitum. Protocols of the study were 
duly approved (approval no. 2014/A243) by 
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Animal Ethical Committee of Peking University.    
In vivo study was executed as per directives of 
European Commission on animal handling [16].       
 
A total of 54 rats were divided in three groups 
(control, standard and test group) of eighteen 
rats each. All the animals were subjected to 
laminectomy (after injecting thiopental sodium 40 
mg/kg) by giving the acute spinal injury by 
compression method (extradural 50 g force clip 
for 10 s at around T2) laterally after giving 
thiopental sodium (40 mg/kg). Immediately the 
control groups were administered the non-
medicated implant. The test group received the 
polymeric implant of MPSS (50 mg/Kg body 
weight; i.t.) near injury. MPSS was injected i.v. at 
30 mg/Kg body weight in the Standard after 1 h 
of injury (and given the same at every alternate 
day for one week). At the end of 7 days, the 
locomotor activity was observed by the 
performance of rats in Horizontal Bar. The 
experiment was performed on an apparatus with 
a horizontal bar (2 mm diameter; 40 cm long) 
fitted on two support of 50 cm height. By holding 
the mouse tail it was left on the bar with the help 
of its forepaw’s contact in the center of the bar. 
The time spent by rats in horizontal bar was 
studied and scoring was done on the basis of 
following scale:  1-5 sec = 1; 6 - 10 sec = 2; 11 - 
20 sec = 3; 21- 30 sec = 4; > 30 sec = 5; bar 




The results are expressed as mean ± standard 





Chitosan and alginate blend based polymeric 
implants loaded with MPSS were prepared by 
ionotropic gelation method and characterized for 
drug loading, in vitro drug release and in vivo 
performance in traumatic spinal injured rats. The 
method used is simple and easy to reproduce. 
 
The implants were observed as the light pale 
solid matrix with smooth texture. Implants 
showed 86.56 ± 2.07 % drug loading. Drug 
release was 89.29 ± 1.25 % at the end of 7 days 
(Fig 1). Alginate chitosan blend of polymer have 
been reported to provide controlled drug release 
in various previous studies [17,18]. 
 
Locomotor activity is governed by motor nerve 
activity which is adversely affected by spinal 
injury. Therefore, motor activity of the traumatic 
spinal injured rats were compared after 
administering the prepared implants of MPSS 
with that of standard (i.v. MPSS). Motor function 
was evaluated in terms of the rat’s movement in 
a horizontal bar (Table 2). After the 24 hours no 
improvement in activity was observed in any 
group (activity score 0.40 ± 0.02). Moreover, out 
of 18 rats in control group only 7 survived. All 18 
survived in standard (activity score: 0.41 ± 0.20) 
and 16 survived in test group (activity score: 0.42 
± 0.12) with insignificant improvement. As 
survival was quite good in test group animals it 
was inferred that the polymeric device was well 
tolerated in the subjects. 
 
On the day 4, there was still no significant 
improvement in activity (activity score: 0.42 ± 
0.12) in control group which remain only 4. The 
standard group showed activity score of 2.45 ± 
1.20 at the end of day 4 with little tail lifting. On 
the other hand the test group showed better 
activity than that of standards with activity score 




Fig 1: In vitro drug release study of polymeric implant of Methylprednisolone in pH 7.4 phosphate buffer 
 
Yin et al 
Trop J Pharm Res, September 2016; 15(9): 1836  
 
Table 2: In vivo locomotor activity of polymeric implant of MPSS in traumatic spinal injured rats 
 
Group Activity score** 
Day 1 a Day 4b Day 7c 
Control  0.40±0.02 0.42±0.12 0.45±0.10 
Standard  0.41±0.20 d 2.45±1.20 d 4.62±0.25d 
Test 0.42±0.12 d 3.20±0.20 d 4.75±0.02d 
* MPSS: methylprednisolone sodium succinate i.v., 50 mg/Kg body weight; ** Activity scoring: 1 - 5 sec = 1; 6-10 
sec = 2; 11 - 20 sec = 3; 21 - 30 sec = 4; > 30 sec = 5; bar support touch with forepaw = 5; n = 18. aAt day 1 only 
7 survived out of 18 in control; all 18 survived in standard while 16 survived in test group.; b At day 4 only 7 
survived in control; no further deaths was there in standard and test group.; c At day 7 only 2 survived in control 
but there was no death in standard and test; d p < 0.05 vs. control 
 
At the end of the day 7 only 2 rats survived in 
control with no sign of improvement in the activity 
score (0.45 ± 0.10). The standard group showed 
an activity score of 4.62 ± 0.25 while the test 
group had an activity score of 4.75 ± 0.02 which 





It has been shown by various previous studies 
that the implants prepared from biodegradable 
polymers are one of the most potential 
approaches of delivering drugs to target site. 
Delivering a drug in the microenvironment of 
target site ensures the maximum drug utilization 
with minimum drug dosage. Moreover, as drug is 
not distributed peripherally much, the adverse 
effects of the drug are also minimized [19,20]. In 
polymeric devices selection of biocompatible 
polymers and/or solvents is crucial to minimize 
chances of rejection of the devices by the 
subjects [21]. 
 
Biodegradable polymers have been investigated 
for various pharmaceutical drug delivery 
systems. Apart from being nontoxic, non-
mutagenic and non-cytotoxic, the biodegradable 
polymers are metabolized in the body and 
eliminated by normal physiological pathways 
[22,23]. Methylprednisolone is a potent anti-
inflammatory glucocorticoid which is used as a 
very first line treatment in cases of post traumatic 
SCI. It was reported to show significant recovery 
from primary tissue damage and secondary 
neuropathic pain and inflammation. Studies have 
also shown improvement in motor nerve activity 
with use of Mp in SCI [14,15,24].  
 
Most of the studies have demonstrated positive 
effects of MPSS in SCI with parenteral (i.v.) 
administration. But high dosage of MPSS is also 
associated with the systemic adverse effects. 
Therefore, alternative routes or devices (like 
biodegradable implants) for administration of 
MPSS have been explored and investigated. 
Biodegradable implantable drug delivery 
techniques have been designed to release drugs 
at the targeted site like fractured vertebra, injured 
spinal cord etc. for prolonged period of time. But 
it requires surgical procedure for administering 
the implant devices to the target site [2-4].  
 
In a recent study, in situ gel prepared from 
chitosan and PLGA (1:14) was found to be very 
potential in the post traumatic spinal injuries. The 
in situ gel showed high drug content, satisfactory 
rheological properties, prolonged drug release 
and the best in vivo anti-inflammatory and motor 
function activity performance [25]. This recent 
study also supported the use of implant for 
delivering MPSS in SCI. The prepared implant of 
MPSS showed the high % drug loading which is 
the prerequisite for the drug delivery systems for 
accommodating desired quantity of drug within 
the delivery matrix for subsequent slow diffusion 
or release of the drug. The in vitro drug release 
study of the prepared implant showed a slow and 
prolonged drug release which had been well 
supported by the various previous studies 
dealing with the alginate chitosan polymeric drug 
delivery matrix [17,18]. The prepared implants of 
MPSS showed motor activity in the traumatic 
spinal injured rats that was comparable to that of 




The findings of this study indicate that MPSS 
implants show high drug loading, prolonged in 
vitro drug release and good tolerance in rats. The 
implants also produces significant recovery in 
traumatic spinal injured rats. These implants may 
be useful for providing prolonged drug release 
and improved recovery in patients of traumatic 
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